CDC/ACIP [to 3 Nov 2018 ]

CDC/ACIP [to 3 Nov 2018 ]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

MMWR News Synopsis for November 2, 2018

Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel

The Advisory Committee on Immunization Practices updated its recommendations on the use of hepatitis A (HepA) vaccine for postexposure prophylaxis and the use of HepA vaccine in infants prior to international travel. Postexposure prophylaxis (PEP) with HepA vaccine or immune globulin (IG) prevents hepatitis A virus infection (HAV) if given within two weeks of exposure. In February 2018, the Advisory Committee on Immunization Practices (ACIP) approved an update of recommendations for use of HepA vaccine for PEP in healthy persons 12 months and older. In addition to HepA vaccine, IG may be administered to persons over 40 years of age, depending on the provider’s risk assessment. HepA vaccine efficacy and safety in infants and the benefits of protection against HAV before international travel were also reviewed. ACIP recommended that HepA vaccine be administered to infants aged 6–11 months traveling outside the United States when protection against HAV is recommended. The updated recommendations specify new guidance for administering PEP for people over 40, and infants for international travel.